Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder

Takaharu Azekawa, Shizuko Ohashi, Akira ItamiShioiri Mental Clinic, Yokosuka-shi, Kanagawa-ken, JapanBackground: Effectiveness of a drug is a key concept dependent on efficacy, safety, and tolerability. Time to discontinuation of treatment is also representative of effectiveness. We investigated dif...

Full description

Bibliographic Details
Main Authors:	Azekawa T, Ohashi S, Itami A
Format:	Article
Language:	English
Published:	Dove Medical Press 2011-11-01
Series:	Neuropsychiatric Disease and Treatment
Online Access:	http://www.dovepress.com/comparative-study-of-treatment-continuation-using-second-generation-an-a8686

Similar Items

Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil
by: Izabela Fulone, et al.
Published: (2021-05-01)

Metabolic screening in primary care for patients with schizophrenia or schizoaffective disorder and taking antipsychotic medication
by: Ross Lawrenson, et al.
Published: (2020-01-01)

Adherence and continuation of treatment with first- and second-generation antipsychotics in schizophrenia
by: Nisha Warikoo, et al.
Published: (2014-01-01)

The continuing story of schizophrenia and schizoaffective disorder: One condition or two?
by: Leah I. Hartman, et al.
Published: (2019-06-01)

Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder
by: Ichinose M, et al.
Published: (2021-04-01)

Representations of the parental family in patients with schizoaffective disorder and schizophrenia
by: Kholmogorova A.B., et al.
Published: (2013-10-01)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
by: Marian S. McDonagh, et al.
Published: (2020-12-01)

Neurophysiological distinction between schizophrenia and schizoaffective disorder
by: Daniel H Mathalon, et al.
Published: (2010-01-01)

Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder.
by: Dusan Hirjak, et al.
Published: (2016-01-01)

Comparing tolerability profile of second generation antipsychotics in schizophrenia and affective disorders : a meta-analysis
by: Moteshafi, Hoda
Published: (2012)

Comparing tolerability profile of second generation antipsychotics in schizophrenia and affective disorders : a meta-analysis
by: Moteshafi, Hoda
Published: (2012)

Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course
by: L. A. Ivanova, et al.
Published: (2019-05-01)

Paranoid schizophrenia versus schizoaffective disorder: Neuropsychological aspects
by: Leposavić Ljubica, et al.
Published: (2015-01-01)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
by: Sajatovic M, et al.
Published: (2018-06-01)

Social and Neurocognitive Deficits in Remitted Patients with Schizophrenia, Schizoaffective and Bipolar Disorder
by: Liana Dehelean, et al.
Published: (2021-03-01)

Intellectual functioning in first-episode schizophrenia, schizoaffective disorder and bipolar disorder
by: Alamian, Golnoush
Published: (2015)

Rapid initiation of quetiapine well tolerated as compared with the conventional initiation regimen in patients with schizophrenia or schizoaffective disorders
by: Cheng-Cheng Hsiao, et al.
Published: (2011-11-01)

A comparative study on metabolic syndrome in patients with schizophrenia treated using first-generation and second-generation antipsychotics
by: Dinesh Panati, et al.
Published: (2020-01-01)

Examination Of Working Life In Patients With Schizophrenia And Schizoaffective Disorder: A Pilot Study
by: Beyza Nur Kaytaz, et al.
Published: (2017-09-01)

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
by: Hoffmann Vicki, et al.
Published: (2010-11-01)

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder
by: Walter Deberdt, et al.
Published: (2008-09-01)

Thought and language disorders in very early onset schizophrenia, schizoaffective disorder and bipolar disorder
by: Telma Pantano, et al.

Differential Diagnosis of Schizophrenia and Schizoaffective Disorder: the Role of Emotional Content of Memories
by: Malahat Amani, et al.
Published: (2018-01-01)

Social function in schizophrenia and schizoaffective disorder: Associations with personality, symptoms and neurocognition
by: Lysaker Paul H, et al.
Published: (2004-03-01)

Relationship between attention and social functioning in individuals with schizophrenia or schizoaffective disorder
by: Ott, Fred Julius
Published: (2009)

Relationship between attention and social functioning in individuals with schizophrenia or schizoaffective disorder
by: Ott, Fred Julius
Published: (2009)

Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder
by: Atiqul Haq Mazumder, et al.
Published: (2021-05-01)

Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications
by: M S Karthik, et al.
Published: (2014-01-01)

Combining ECT and clozapine in the treatment of clozapine-refractory schizophrenia and schizoaffective disorder – a pilot study
by: L Koen, et al.
Published: (2008-12-01)

Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder
by: Hardy Thomas A, et al.
Published: (2008-09-01)

Use of Natural Language Processing to identify Obsessive Compulsive Symptoms in patients with schizophrenia, schizoaffective disorder or bipolar disorder
by: David Chandran, et al.
Published: (2019-10-01)

Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder
by: E.R. Bychkov, et al.
Published: (2011-11-01)

The structure and dynamic of the defensive organization the personality in Paranoid Schizophrenia, Schizoaffective and Affective Disorders
by: I M Kadyrov, et al.
Published: (2011-03-01)

Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder
by: Danny Boerrigter, et al.
Published: (2017-09-01)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01)

Group and sex differences in social cognition in bipolar disorder, schizophrenia/schizoaffective disorder and healthy people
by: Guillem Navarra-Ventura, et al.
Published: (2021-08-01)

Remission structure in schizoaffective disorder
by: Olga I. Syerikova, et al.
Published: (2020-10-01)

Illness Management and Recovery : Implementation and evaluation of a psychosocial program for schizophrenia and schizoaffective disorder
by: Färdig, Rickard
Published: (2012)

Protocadherin11X/Y, a candidate gene-pair for schizophrenia and schizoaffective disorder
by: Giouzeli, Maria
Published: (2005)

Visuospatial and Sensory Integration Tasks in Patients With Schizophrenia or Schizoaffective Disorder: Relationship to Body Mass Index and Smoking
by: Tyler S. Vanderhoof, et al.
Published: (2018-10-01)